The Impact of Methylphenidate on Pubertal Maturation and Bone Age in ADHD Children and Adolescents: Results from the ADHD Drugs Use Chronic Effects (ADDUCE) Project
Restricted accessResearch articleFirst published online March, 2024
The Impact of Methylphenidate on Pubertal Maturation and Bone Age in ADHD Children and Adolescents: Results from the ADHD Drugs Use Chronic Effects (ADDUCE) Project
The short-term safety of methylphenidate (MPH) has been widely demonstrated; however the long-term safety is less clear. The aim of this study was to investigate the safety of MPH in relation to pubertal maturation and to explore the monitoring of bone age.
Method:
Participants from ADDUCE, a two-year observational longitudinal study with three parallel cohorts (MPH group, no-MPH group, and a non-ADHD control group), were compared with respect to Tanner staging. An Italian subsample of medicated-ADHD was further assessed by the monitoring of bone age.
Results:
The medicated and unmedicated ADHD groups did not differ in Tanner stages indicating no higher risk of sexual maturational delay in the MPH-treated patients. The medicated subsample monitored for bone age showed a slight acceleration of the bone maturation after 24 months, however their predicted adult height remained stable.
Conclusion:
Our results do not suggest safety concerns on long-term treatment with MPH in relation to pubertal maturation and growth.
AdrianiW.LeoD.GuarinoM.NatoliA.Di ConsiglioE.De AngelisG.TrainaE.TestaiE.Perrone-CapanoC.LaviolaG. (2006). Short-term effects of adolescent methylphenidate exposure on brain striatal gene expression and sexual/endocrine parameters in male rats. Annals of the New York Academy of Science, 1074, 52–73. https://doi.org/10.1196/annals.1369.005
ArnstenA. F. T.PliszkaS. R. (2011). Catecholamine influences on prefrontal cortical function: Relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacology, Biochemistry & Behavior, 99(2), 211–216. https://doi.org/10.1016/j.pbb.2011.01.020
4.
BanaschewskiT.JohnsonM.NagyP.OteroI. H.SoutulloC. A.YanB.ZuddasA.CoghillD. R. (2018). Growth and puberty in a 2-year open-label study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. CNS Drugs, 32(5), 455–467. https://doi.org/10.1007/s40263-018-0514-8
5.
BereketA.TuranS.KaramanM. G.HaklarG.OzbayF.YazganM. Y. (2005). Height, weight, IFGSI, IGFBPS3 and thyroid functions in prepubertal children with attention deficit hyperactivity disorder: Effect of methylphenidate treatment. Hormone Research, 63(4), 159–164. https://doi.org/10.1159/000084683
6.
BiedermanJ.FaraoneS. V.MonuteauxM. C.PlunkettE. A.GiffordJ.SpencerT. (2003). Growth deficits and attention-deficit/hyperactivity disorder revisited: Impact of gender, development, and treatment. Pediatrics, 111(5 Pt 1), 1010–1016. https://doi.org/10.1542/peds.111.5.1010
7.
BiedermanJ.SpencerT. J.MonuteauxM. C.FaraoneS. V. (2010). A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. The Journal of Pediatrics, 157(4), 635–640. https://doi.org/10.1016/j.jpeds.2010.04.025
8.
CacciariE.MilaniS.BalsamoA., & SIEDP. (2002). Directive council 2002-03: Italian cross sectional growth charts for height, weight and BMI (6-20 yr). European Journal of Clinical Nutrition, 56, 171–180
9.
CansuA.EkinciO.EkinciO.SerdarogluA.ErdoganD.CoskunZ. K.GürgenS. G. (2011). Methylphenidate has dose-dependent negative effects on rat spermatogenesis: decreased round spermatids and testicular weight and increased expression and apoptosis. Human & Experimental Toxicology, 30, 1592–1600. https://doi.org/10.1177/0960327110394224
10.
CarucciS.BaliaC.GaglianoA.LampisA.BuitelaarJK.DanckaertsM.DittmannR.W.GarasP.HollisC.InglisS.KonradK.KovshoffH.LiddleE.B.McCarthyS.NagyP.PaneiP.RomanielloR.UsalaT.WongI.C.K.BanaschewskiT.Sonuga-BarkeE.CoghillD.ZuddasA.; ADDUCE Consortium. (2021) Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 120, 509–525. https://doi.org/10.1016/j.neubiorev.2020.09.031
11.
CavalloF.MohnA.ChiarelliF.GianniniC. (2021). Evaluation of bone age in children: A mini-review. Frontiers in Pediatrics, 9, 580314. https://doi.org/10.3389/fped.2021.580314
12.
ChildressA. C.CutlerA. J.PatelM.OhC. (2023). Analysis of growth velocity in children with attention-deficit/hyperactivity disorder treated for up to 12 months with serdexmethylphenidate/dexmethylphenidate. J Child Adolesc Psychopharmacol, 33(4), 134–142. https://doi.org/10.1089/cap.2023.0012
13.
CoghillD. R.BanaschewskiT.SoutulloC.CottinghamM. G.ZuddasA. (2017). Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. European Child & Adolescent Psychiatry, 26(11), 1283–1307. https://doi.org/10.1007/s00787-017-0986-y
14.
CorteseS.AdamoN.Del GiovaneC.Mohr-JensenC.HayesA. J.CarucciS.AtkinsonL. Z.TessariL.BanaschewskiT.CoghillD.HollisC.SimonoffE.ZuddasA.BarbuiC.PurgatoM.SteinhausenH.C.ShokranehF.XiaJ.CiprianiA. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. Lancet Psychiatry, 5(9), 727–738. https://doi.org/10.1016/S2215-0366(18)30269-4
15.
CorteseS.HoltmannM.BanaschewskiT.BuitelaarJ.CoghillD.DanckaertsM.DittmannR. W.GrahamJ.TaylorE.SergeantJ., & European ADHD Guidelines Group. (2013). Practitioner review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. Journal of Child Psychology & Psychiatry & Allied Disciplines, 54(3), 227–246. https://doi.org/10.1111/jcpp.12036
16.
DesmanglesJ. C.LappeJ. M.LipaczewskiG.HaynatzkiG. (2006). Accuracy of pubertal Tanner staging self-reporting. Journal of Pediatric Endocrinology Metabolism, 19(3), 213–221. https://doi.org/10.1515/jpem.2006.19.3.213
17.
DuongK. L.YangB. R.YunH. Y.ChaeJ. W. (2023). Effect of methylphenidate on height in pediatric attention-deficit hyperactivity disorder patients: A systematic review and meta-analysis. European Child & Adolescent Psychiatry. Advance online publication. https://doi.org/10.1007/s00787-023-02273-x
FaraoneS. V.BiedermanJ.MorleyC. P.SpencerT. J. (2008). Effect of stimulants on height and weight: A review of the literature. Journal of the American Academy of Child & Adolescent Psychiatry, 47(9), 994–1009. https://doi.org/10.1097/CHI.ObO13e31817eOea7
22.
FrankeB.MicheliniG.AshersonP.BanaschewskiT.BilbowA.BuitelaarJ. K.CormandB.FaraoneS. V.GinsbergY.HaavikJ.KuntsiJ.LarssonH.LeschK. P.Ramos-QuirogaJ. A.RéthelyiJ. M.RibasesM.ReifA. (2018). Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. European Neuropsychopharmacology, 28(10), 1059–1088. https://doi.org/10.1016/j.euroneuro.2018.08.001
23.
FredriksenM.HalmoyA.FaraoneS. V.HaavikJ. (2013). Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: A review of controlled and naturalistic studies. European Neuropsychopharmacology, 23, 508–527. https://doi.org/10.1016/j.euroneuro.2012.07.016
24.
GadowK. D.SverdJ.SprafkinJ.NolanE. E.GrossmanS. (1999). Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry, 56(4), 330–336. https://doi.org/10.1001/archpsyc.56.4.330
25.
GharibH.CookD. M.SaengerP. H.BengtssonB. A.FeldS.NippoldtT. B.RodbardH. W.SeibelJ. A.VanceM. L.ZimmermanD. (2003). American association of clinical endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children–2003 update. Endocrine Practice, 9, 64–76.
26.
GrahamJ.BanaschewskiT.BuitelaarJ.CoghillD.DanckaertsM.DittmannR. W.DöpfnerM.HamiltonR.HollisC.HoltmannM.Hulpke-WetteM.LecendreuxM.RosenthalE.RothenbergerA.SantoshP.SergeantJ.SimonoffE.Sonuga-BarkeE.WongI. C., . . . & European Guidelines Group. (2011). European guidelines on managing adverse effects of medication for ADHD. European Child & Adolescent Psychiatry, 20(1), 17–37. https://doi.org/10.1007/s00787-010-0140-6
27.
GreenfieldB.HechtmanL.StehliA.WigalT. (2014). Sexual maturation among youth with ADHD and the impact of stimulant medication. European Child & Adolescent Psychiatry, 23(9), 835–839. https://doi.org/10.1007/s00787-014-0521-3
28.
HarstadE. B.WeaverA. L.KatusicS. K.ColliganR. C.KumarS.ChanE.VoigtR. G.BarbaresiW. J. (2014). ADHD, stimulant treatment, and growth: A longitudinal study. Pediatrics, 134, e935–e944. https://doi.org/10.1542/peds.2014-0428
29.
HartmanM. L.VeldhuisJ. D.ThornerM. O. (1993). Normal control of growth hormone secretion. Hormone Research, 40, 37–47. https://doi.org/10.1159/000183766
30.
HechtmanL.WeissG.PerlmanT. (1984). Young adult outcome of hyperactive children who received long-term stimulant treatment. Journal of American Academy of Child Psychiatry, 23(3), 261–269. https://doi.org/10.1016/s0002-7138(09)60501-x
31.
HowardJ. T.WalickK. S.RiveraJ. C. (2015). Preliminary evidence of an association between ADHD medications and diminished bone health in children and adolescents. Journal of Pediatric Orthopaedics, 37(5), 348–354. https://doi.org/10.1097/BPO.0000000000000651
32.
HysekC. M.SimmlerL. D.SchillingerN.MeyerN.SchmidY.DonzelliM.GrouzmannE.LiechtiM. E. (2014). Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. International Journal of Neuropsychopharmacology, 17, 371–381. https://doi.org/10.1017/S1461145713001132
33.
InglisS. K.CarucciS.GarasP.HägeA.BanaschewskiT.BuitelaarJ. K.DittmannR. W.FalissardB.HollisC.KovshoffH.LiddleE.McCarthyS.NagyP.NeubertA.RosenthalE.Sonuga-BarkeE.WongI.ZuddasA.CoghillD. C., & ADDUCE Consortium. (2016). Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: The attention deficit hyperactivity disorder drugs use chronic effects (ADDUCE) study. BMJ Open, 6(4), e010433. https://doi.org/10.1136/bmjopen-2015-010433
34.
JaruratanasirikulS.KreetapiromP.TassanakijpanichN.SriplungH. (2015). Reliability of pubertal maturation self-assessment in a school-based survey. Journal of Pediatric Endocrinology and Metabolism, 28(3–4), 367–374. https://doi.org/10.1515/jpem-2014-0053
35.
KaramanM. I.KayaC.CaskurluT.GuneyS.ErgenekonE. (2005). Measurement of pediatric testicular volume with Prader orchidometer: Comparison of different hands. Pediatric Surgery International, 21(7), 517–520. https://doi.org/10.1007/s00383-005-1470-1
36.
KhanK.ElayappenA. S. (2012). Bone growth estimation using radiology (Greulich–Pyle and Tanner–Whitehouse Methods). In PreedyV. R. (Ed.) Handbook of growth and growth monitoring in health and disease (pp. 2937–2953). Springer. http://link.springer.com/chapter/10.1007/978-1-4419-1795-9_176
37.
KhoubbiehF.ErdoganC. S.OnelT.YildirimE.SumerE.YabaA.YilmazB. (2023). Effect of methylphenidate on the onset of puberty and reproductive organ development in rats. Physiology & Behavior, 266, 114204. https://doi.org/10.1016/j.physbeh.2023.114204
38.
KilgoreB. S.DickinsonM. A.BurnettC. R.LeeJ.SchedewieH. K.EldersM. J. (1979). Alterations in cartilage metabolism by neurostimulant drugs. Journal of Pediatrics, 94, 542–545.
39.
KleinR. G.LandaB.MattesJ. A.KleinD. F. (1988). Methylphenidate and growth in hyperactive children, in a controlled withdrawal study. Archives in General Psychiatry, 45(12), 1127–1130.
40.
KooijS. J.BejerotS.BlackwellA.CaciH.Casas-BruguéM.CarpentierP. J.EdvinssonD.FayyadJ.FoekenK.FitzgeraldM.GaillacV.GinsbergY.HenryC.KrauseJ.LensingM. B.ManorI.NiederhoferH.Nunes-FilipeC.OhlmeierM. D.OswaldP.PallantiS.PehlivanidisA.Ramos-QuirogaJ. A.RastamM.Ryffel-RawakD.StesS.AshersonP. (2010). European consensus statement on diagnosis and treatment of adult ADHD: The european network adult ADHD. BMC Psychiatry, 10, 67. https://doi.org/10.1186/1471-244X-10-67
41.
KramerJ. R.LoneyJ.PontoL. B.RobertsM. A.GrossmanS. (2000). Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems. Journal of the American Academy of Child & Adolescent Psychiatry, 39(4), 517–524. https://doi.org/10.1097/00004583-200004000-00022
42.
LahatE.WeissM.Ben-ShlomoA.EvansS.BistritzerT. (2000). Bone mineral density and turnover in children with attention-deficit hyperactivity disorder receiving methylphenidate. Journal of Child Neurology, 15(7), 436–439. https://doi.org/10.1177/088307380001500702
LiuX.HerbisonA. E. (2013). Dopamine regulation of gonadotropin-releasing hormone neuron excitability in male and female mice. Endocrinology, 154, 340–350. https://doi.org/10.1210/en.2012-1602
45.
LurieS.O’QuinnA. (1991). Neuroendocrine responses to methylphenidate and d-amphetamine: Applications to attention deficit disorder. Journal of Neuropsychiatry, 3, 41–50.
46.
ManK. K. C.HägeA.BanaschewskiT.InglisS. K.BuitelaarJ.CarucciS.DanckaertsM.DittmannR. W.FalissardB.GarasP.HollisC.KonradK.KovshoffH.LiddleE.McCarthyS.NeubertA.NagyP.RosenthalE.Sonuga-BarkeE. J. S., . . . & ADDUCE Consortium. (2023). Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the attention deficit hyperactivity disorder drugs use chronic effects (ADDUCE) study. Lancet Psychiatry, 10(5), 323–333. https://doi.org/10.1016/S2215-0366(23)00042-1
47.
MarshallW. A.TannerJ. M. (1970). Variations in the pattern of pubertal changes in boys. Archives of Disease in Childhood, 45239, 13–23.
48.
MullerE. E.CocchiD.LocatelliV. (2011). Growth hormone and somatomedins during lifespan. Springer-Verlag
49.
NovairaH. J.YatesM.DiaczokD.KimH.WolfeA.RadovickS. (2011). The gonadotropin-releasing hormone cell-specific element is required for normal puberty and estrous cyclicity. Journl of Neuroscience, 31(9), 3336–3343. https://doi.org/10.1523/JNEUROSCI.5419-10.2011
50.
PeyreH.HoertelN.CorteseS.AcquavivaE.LimosinF.DelormeR. (2013). Long-term effects of ADHD medication on adult height: Results from the NESARC. The Journal of Clinical Psychiatry, 74, 1123–1124. https://doi.org/10.4088/JCP.13l08580
51.
PoultonA.BriodyJ.McCorquodaleT.MelzerE.HerrmannM.BaurL. A.DuqueG. (2012). Weight loss on stimulant medication: How does it affect body composition and bone metabolism? A prospective longitudinal study. International Journal of Pediatric Endocrinology, 2012, 30.
52.
PoultonA. S.BuiQ.MelzerE.EvansR. (2016). Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: A prospective cohort study. International Clinical Psychopharmacology, 31(2), 93–99. https://doi.org/10.1097/YIC.0000000000000109
53.
PoultonA. S.MelzerE.TaitP. R.GarnettS. P.Cow-ellC. T.BaurL. A.ClarkeS. (2013). Growth and pubertal development of adolescent boys on stimulant medication for attention deficit hyperactivity disorder. Medical Journal of Australia, 198(1), 29–32. https://doi.org/10.5694/mja12.10931
54.
RamanS. R.ManK. K. C.BahmanyarS.BerardA.BilderS.BoukhrisT.BushnellG.CrystalS.FuruK.KaoYangY. H.KarlstadO.KielerH.KubotaK.Chia-Cheng LaiE.MartikainenJ. E.MauraG.MooreN.MonteroD.NakamuraH.. . . & WongI. C. K. (2018). Trends in attention-deficit hyperactivity disorder medication use: A retrospective observational study using population-based databases. Lancet Psychiatry, 5, 824–835. https://doi.org/10.1016/S2215-0366(18)30293-1
55.
RichardsJ. R.AlbertsonT. E.DerletR. W.LangeR. A.OlsonK. R.HorowitzB. Z. (2015). Treatment of toxicity from amphetamines, related derivatives, and analogues: A systematic clinical review. Drug and Alcohol Dependence, 150, 1–13. https://doi.org/10.1016/j.drugalcdep.2015.01.040
56.
RollofL.ElfvingM. (2012). Evaluation of self-assessment of pubertal maturation in boys and girls using drawings and orchidometer. Journal of Pediatric Endocrinology and Metabolism, 25(1–2), 125–129. https://doi.org/10.1515/jpem.2011.440
57.
RosenthalE. A.HinshawS. P. (2023). Pubertal timing in adolescents with ADHD: Extension and replication in an all-female sample. European Child & Adolescent Psychiatry. Advance online publication. https://doi.org/10.1007/s00787-023-02239-z
58.
SaferD. J.AllenR. P.BarrE. (1975). Growth rebound after termination of stimulant drugs. Journal of Pediatrics, 86(1), 113–116.
59.
SatterfieldJ. H.CantwellD. P.SchellA.BlaschkeT. (1979). Growth of hyperactive children treated with methylphenidate. Archives of General Psychiatry, 36(2), 212–217.
60.
SchlossbergerN. M.TurnerR. A.IrwinC. E.Jr. (1992). Validity of self-report of pubertal maturation in early adolescents. Journal of Adolescent Health, 13(2), 109–113. https://doi.org/10.1016/1054-139x(92)90075-m
61.
SchmitzK. E.HovellM. F.NicholsJ. F.IrvinV. L.KeatingK.SimonG. M.GehrmanC.JonesK. L. (2004). A validation study of early adolescents’ pubertal self-assessments. Journal of Early Adolescence, 24(4), 357–384. https://doi.org/10.1177/0272431604268531
62.
SchultzF. R.HayfordJ. T.WolraichM. L.HintzR. L.ThompsonR. G. (1982). Methylphenidate treatment of hyperactive children: Effects on the hypothalamic-pituitary-somatomedin axis. Pediatrics, 70(6), 987–992.
63.
ShawM.HodgkinsP.CaciH.YoungS.KahleJ.WoodsA. G.ArnoldL. E. (2012). A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: Effects of treatment and non-treatment. BMC Medical, 10, 99. https://doi.org/10.1186/1741-7015-10-99
64.
ShaywitzB. A.ShaywitzS. E.SebrechtsM. M.AndersonG. M.CohenD. J.JatlowP.YoungJ. G. (1990). Growth hormone and prolactin response to methylphenidate in children with attention deficit disorder. Life Science, 46, 625–633. https://doi.org/10.1016/0024-3205(90)90131-a
65.
SpencerT.BiedermanJ.WilensT.HardingM.OdonnellB. A. D.GriffinS. (1996). Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. Journal of the American Academy of Child and Adolescent Psychiatry, 35(4), 409–432. https://doi.org/10.1097/00004583-199604000-00008
66.
StorebøO. J.PedersenN.RamstadE.KielsholmM. L.NielsenS. S.KroghH. B.Moreira-MaiaC. R.MagnussonF. L.HolmskovM.GernerT.SkoogM.RosendalS.GrothC.GilliesD.Buch RasmussenK.GauciD.ZwiM.KirubakaranR.HåkonsenS. J.GluudC.. . . & GluudC. (2018). Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – Assessment of adverse events in non-randomised studies. Cochrane Database of Systematic Reviews, 5(5), Cd012069. https://doi.org/10.1002/14651858.CD012069.pub2
67.
SwansonJ. M.ArnoldL. E.MolinaB. S. G.SibleyM. H.HechtmanL. T.HinshawS. P., et al. (2017). Young adult outcomes in the follow-up of the multi-modal treatment study of attention-deficit/hyperactivity disorder: Symptom persistence, source discrepancy, and height suppression. Journal of Child Psychology and Psychiatry, 58(6), 663–678. https://doi.org/10.1111/jcpp.12684
68.
TannerJ. M.WhitehouseR. H. (1976). Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Archives of Disease in Childhood, 51(3), 170–179. https://doi.org/10.1136/adc.51.3.170
69.
TannerJ. M.WhitehouseR. H.MarshallW. A.CarterB. S. (1975). Prediction of adult height from height, bone age, and occurrence of menarche, at ages 4 to 16 with allowance for midparent height. Archives of Disease in Childhood, 50, 14–26.
70.
TorenP.SilbergeldA.EldarS.LaorN.WolmerL.KorenS.WeitzR.InbarD.ReissA.EshetR.WeizmanR. (1997). Lack of effect of methylphenidate on serum growth hormone (GH), GH-binding protein, and insulin-like growth factor I. Clinical Neuropharmacology, 20(3), 264–269. https://doi.org/10.1097/00002826-199706000-00011
71.
VitielloB. (2008). Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child & Adolescent Psychiatric Clinics of North America, 17(2), 459–474. https://doi.org/10.1016/j.chc.2007.11.010
72.
VolkowN. D.WangG.FowlerJ. S.LoganJ.GerasimovM.MaynardL.DingY.GatleyS. J.GiffordA.FranceschiD. (2001). Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. Journal of Neuroscience, 21, RC121. https://doi.org/10.1523/JNEUROSCI.21-02-j0001.2001
73.
VolkowN. D.WangG.-J.FowlerJ. S.LoganJ.FranceschiD.MaynardL.DingY. S.GatleyS. J.GiffordA.ZhuW.SwansonJ. M. (2002). Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications. Synapse, 43(3), 181–187. https://doi.org/10.1002/syn.10038
74.
WangL. J.HuangY. H.ChouW. J.LeeS. Y.TsaiC. S.LeeM. J.ChouM. C. (2021). Potential disturbance of methylphenidate of gonadal hormones or pubescent development in patients with attention-deficit/hyperactivity disorder: A twelve-month follow-up study. Progress in Neuropsychopharmacology and Biological Psychiatry, 108, 110181. https://doi.org/10.1016/j.pnpbp.2020.110181
75.
ZegherF. D.Den BergheG. V.DevliegerH.EggermontE.VeldhuisJ. D. (1993). Dopamine inhibits growth hormone and prolactin secretion in the human newborn. Pediatric Research, 34, 642–645. https://doi.org/10.1203/00006450-199311000-00016
76.
ZhangH.DuM.ZhuangS. (2010). Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics, 41(2), 55–59. https://doi.org/10.1055/s-0030-1261893
